[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gestational-diabetes-mellitus-gdm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gestational-diabetes-mellitus-gdm":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,38,0,25,[9,55,84,115,146,173,198,225,253,291,331,355,380,411,438,466,489,508,531,560,585,606,630,655,680],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":34,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":4},"100645319","diabetes-insulin-gut-enteric-supplementation-trial-100645319",false,"NCT07682077","Diabetes, Insulin, Gut, Enteric Supplementation Trial","Effects of a Kefir Intervention in Pregnancy on Glucose, Insulin, Gestational Diabetes Mellitus, and the Gut Microbiome and Metabolites: A Randomized Controlled Trial","DIGEST","Inclusion Criteria:\n\n* Pregnant individual with a singleton pregnancy\n* 19 years and older of age\n* Gestational age 14,3 weeks or less at enrolment\n* Able and willing to attend four in-person study visits at the PEADS Laboratory: baseline, 18-20 weeks' gestation, 26-28 weeks' gestation, and 1 month postpartum\n* Willing and able to comply with study group assignment, including daily consumption of 250 mL of kefir if assigned to the intervention group\n* Willing to avoid kefir consumption until completion of the 26-28-week study visit if assigned to the control group\n* Willing to provide required biological and clinical samples, including stool samples and glucose\u002Finsulin data, according to the study protocol\n* No probiotic, prebiotic, synbiotic, or antibiotic use during the first trimester or at enrollment\n* Not currently consuming probiotic, prebiotic, synbiotic, or antiobiotic supplements\n* Willing to avoid probiotic, prebiotic, and synbiotic supplements until completion of the 26-28-week study visit.\n* Does not engage in regular moderate-to-vigorous physical activity\n* No recent or active infectious illness or significant gastrointestinal symptoms, including diarrhea or constipation in the first trimester of pregnancy.\n* No history of bariatric surgery\n* Able to communicate in English or French\n* Currently living in Fredericton, New Brunswick, and not planning to relocate before the 1-month postpartum visit\n\nExclusion Criteria:\n\n* Pre-existing metabolic disease affecting glucose regulation, including type 1 diabetes or type 2 diabetes\n* Current use or first trimester use of medications known to alter glucose metabolism, such as metformin or semaglutide\n* Gastrointestinal or inflammatory disease, including Crohn's disease, ulcerative colitis, celiac disease, or diagnosed irritable bowel syndrome\n* Allergy, intolerance, or other contraindication to dairy or components of kefir",true,"FEMALE","19 Years",{"count":22,"type":23},60,"ESTIMATED","INTERVENTIONAL",[26],"NA","Pregnancy is a critical window for metabolic health, and early changes in blood sugar regulation can increase the risk of gestational diabetes mellitus (GDM), which affects both maternal and infant health. At the same time, the maternal gut microbiome changes throughout pregnancy and may play a role in glucose metabolism and insulin resistance. Kefir, a fermented milk drink containing beneficial bacteria and yeasts, may be a simple dietary strategy to support metabolic health during pregnancy, but its role in preventing GDM has not been well studied.\n\nThis study will test whether drinking kefir daily from mid-pregnancy until routine GDM screening can improve glucose and insulin regulation, reduce the incidence of GDM, and modulate the maternal gut microbiome and metabolites, among other outcomes.\n\nPregnant individuals will be randomly assigned to either a kefir group or a control group receiving usual prenatal care. Researchers will collect blood glucose and insulin measures, dietary information, stool samples, and body composition data across pregnancy and postpartum to evaluate metabolic and microbiome-related changes.\n\nAs one of the first studies to examine kefir as an early pregnancy intervention for GDM prevention, this study will help clarify whether a practical, food-based approach can improve maternal metabolic health. The findings may support future nutrition strategies aimed at reducing GDM risk and improving pregnancy outcomes.",[29,30,31,32,33],"Gestational Diabetes Mellitus (GDM)","Blood Glucose","Insulin Resistance, Diabetes","Gut Microbiome","Gut Metabolites",[35,36,37,38,39,40,41,42],"Gestational diabetes mellitus","Pregnancy","Probiotics","Kefir","Gut microbiome","Gut metabolites","Glucose","Insulin","NOT_YET_RECRUITING","2026-06-30",{"date":46,"type":47},"2026-07-02","ACTUAL",{"date":49,"type":23},"2026-06-01",{"date":51,"type":23},"2029-06-01",{"name":53,"class":54},"University of New Brunswick","OTHER",{"id":56,"slug":57,"hasResults":12,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":12,"sex":19,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":24,"phases":64,"briefSummary":65,"conditions":66,"keywords":67,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":76,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100627251","poi-for-mama-a-pilot-to-improve-maternal-microbiome-and-gestational-diabetes-risk-100627251","NCT07446205","Poi for Mama: a Pilot to Improve Maternal Microbiome and Gestational Diabetes Risk","Inclusion Criteria:\n\n* Be at least 10 weeks into their pregnancy\n* have no pre-existing health conditions\n* Be able to read and write in English\n* be at least18 years of age\n* Own a smartphone\n* Live on the windward side of O'ahu\n* Be able to complete study activities\n\nExclusion Criteria:\n\n* Less than 10 weeks pregnant or already in third trimester\n* Have pre-existing health conditions\n* Not able to read and write in English\n* Under 18 years of age\n* Do not own a smartphone\n* Do not live on the windward side of O'ahu\n* Unable to complete study activities","18 Years",{"count":63,"type":23},50,[26],"This investigator-initiated, non-randomized pilot study evaluates the effect of daily consumption of fermented poi on the maternal microbiome and gestational diabetes risk during pregnancy. Fifty pregnant participants between approximately 12 and 24 weeks of gestation will receive one pound of poi daily for four weeks, accompanied by culturally tailored nutrition education delivered via secure text messaging. Changes in vaginal, oral, and rectal microbiome composition, diet quality, gestational diabetes diagnosis, and pregnancy-related outcomes will be assessed and compared with matched controls derived from an existing cohort. This study aims to inform the feasibility and design of a larger culturally grounded dietary intervention for gestational diabetes prevention.",[29,36],[35,29,36,68,69,70,71,72,73,74],"Maternal microbiome","Vaginal microbiome","Fermented foods","Poi","Dietary intervention","Nutrition education","Native Hawaiian and Pacific Islander (NHPI)","RECRUITING",{"date":46,"type":47},{"date":78,"type":47},"2026-06-12",{"date":80,"type":23},"2027-01-31",{"name":82,"class":54},"University of Hawaii",3,{"id":85,"slug":86,"hasResults":12,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":12,"sex":19,"minAge":61,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":24,"phases":94,"briefSummary":95,"conditions":96,"keywords":102,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":114},"100635561","effects-of-leg-ergometer-versus-arm-ergometer-on-blood-glucose-exercise-tolerance-weight-and-psychological-stress-among-gestational-diabetic-patients-100635561","NCT07554287","Effects of Leg Ergometer Versus Arm Ergometer on Blood Glucose, Exercise Tolerance, Weight, and Psychological Stress Among Gestational Diabetic Patients","GDM","Inclusion Criteria:\n\n1. Female participants aged 18-35 years.\n2. Gestational age 14-28 weeks (second trimester).\n3. Singleton pregnancy (confirmed by obstetric record) only to avoid complications of multiple gestation.\n4. Include both primigravida and multigravida (i.e., first or subsequent pregnancy).\n5. Women with first time GDM in pregnancy.\n6. Women with clinical diagnosis of gestational diabetes according to hospital\u002FWHO criteria or hospital diagnostic test.\n7. Blood glucose levels:\n\n   Random capillary glucose \\\u003C 200 mg\u002FdL at screening (to exclude overt diabetes)\n8. Blood pressure:\n\n   * Systolic BP \\\u003C 140 mmHg and Diastolic BP \\\u003C 90 mmHg (no confirmed gestational hypertension).\n   * If BP ≥140\u002F90 mmHg, confirm with repeat measurement 4 hours apart; exclude if persistent.\n9. Willingness to participate and provide written informed consent.\n10. Medically cleared by obstetrician to participate in moderate aerobic exercise.\n\nExclusion Criteria:\n\n1. Previous Cesarean section or medically indicated bed rest.\n2. Known pre-existing diabetes mellitus (Type 1 or Type 2 prior to pregnancy).\n3. Known major obstetric complications (e.g., placenta previa, severe pre- eclampsia).\n4. Patients having multiple\u002Ftwin\u002Ftriplet pregnancies.\n5. Known major fetal anomaly.\n6. Anemic women with Hb \\\u003C 9 g\u002FdL (excluded to prevent exercise intolerance).\n7. Uncontrolled cardiovascular disease, musculoskeletal, or medical contraindications to exercise.\n8. Psychiatric conditions severe enough to hinder informed consent.\n9. Any other medical condition that, in the opinion of the obstetrician, makes participation unsafe.","35 Years",{"count":93,"type":23},108,[26],"The current study is a single-blind, parallel-group randomized controlled trial involving 108 participants with diabetes during pregnancy. The trial will compare leg ergometer with arm ergometer. Interventions will be delivered three times per week for eight weeks. The primary outcomes are glucose, exercise tolerance, weight, and psychological stress. Assessments will be conducted at baseline and after eight weeks. The trial will be carried out at Jinnah hospital, Services hospital, Sir Ganga Ram Hospital, Lahore. The hypothesis is that the leg ergometer including aerobic exercise will result in greater reduction in glucose and exercise tolerance, weight and stress management than arm ergometer.",[97,98,99,29,100,101],"Diabetes During Pregnancy","Pregnancy Complications","Pregnancy in Diabetes","Diabetes Complication","Gestational",[103,104,89,101],"gestational diabetes","diabetes in pregnancy","2026-06-16",{"date":107,"type":47},"2026-06-18",{"date":109,"type":47},"2026-05-26",{"date":111,"type":23},"2026-10-15",{"name":113,"class":54},"Lahore University of Biological and Applied Sciences",1,{"id":116,"slug":117,"hasResults":12,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":18,"sex":19,"minAge":61,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":24,"phases":124,"briefSummary":125,"conditions":126,"keywords":131,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":114},"100641377","polyphenol-intake-mediterranean-diet-adherence-and-oxidative-stress-in-pregnancy-100641377","NCT07656532","Polyphenol Intake, Mediterranean Diet Adherence, and Oxidative Stress in Pregnancy","Effect of Polyphenol Intake and Adherence to the Mediterranean Diet on Oxidative Stress During Pregnancy","PREGPOLY","Inclusion Criteria:\n\n* Pregnant women aged 18 years or older.\n* Singleton pregnancy.\n* Gestational age between 8 and 11 weeks at enrollment.\n* Receiving prenatal care within the Salamanca Health Area.\n* Able to understand the study information and provide written informed consent.\n* No clinical restrictions that would contraindicate dietary modifications.\n\nExclusion Criteria:\n\n* Medical or obstetric conditions that contraindicate dietary modifications.\n* Active metabolic, renal, or hepatic disease.\n* Severe hyperemesis gravidarum or gastrointestinal disorders limiting food intake.\n* Allergy or intolerance to cocoa.\n* Habitual high cocoa or chocolate consumption (\\>30 g\u002Fday).\n* Multiple pregnancy.\n* Severe obstetric complications diagnosed before enrollment.\n* Inability to comply with study procedures, attend follow-up visits, or communication barriers that could interfere with participation.",{"count":22,"type":23},[26],"This study is a randomized controlled clinical trial designed to evaluate the effect of a polyphenol-rich dietary intervention during pregnancy on endothelial function, oxidative stress biomarkers, and maternal and neonatal outcomes.\n\nPregnancy is associated with metabolic and vascular adaptations, and complications such as gestational diabetes and hypertensive disorders are linked to endothelial dysfunction and increased oxidative stress. Dietary factors, particularly adherence to the Mediterranean diet and intake of polyphenol-rich foods, may play a protective role.\n\nPregnant women will be randomly assigned to either an intervention group or a control group. The intervention consists of daily consumption of 10 g of natural non-alkalized cocoa and structured dietary counseling aimed at achieving at least five daily servings of fruits and vegetables, alongside general Mediterranean diet recommendations.\n\nThe intervention will last 12 weeks, from early to mid-pregnancy. Biomarkers of endothelial function and oxidative stress will be measured at different time points, along with clinical maternal outcomes (including gestational diabetes and hypertensive disorders) and neonatal outcomes.\n\nThe aim is to determine whether this dietary intervention improves endothelial function, reduces oxidative stress, and contributes to better pregnancy outcomes.",[36,29,127,128,129,130],"Preeclampsia","Hypertension, Pregnancy-Induced","Oxidative Stress","Endothelial Dysfunction",[132,133,134,135,136,137],"Mediterranean diet","Polyphenols","Cocoa supplementation","Oxidative stress","Endothelial function","Randomized controlled trial","2026-06-14",{"date":107,"type":47},{"date":141,"type":23},"2026-09-01",{"date":143,"type":23},"2028-10-01",{"name":145,"class":54},"University of Salamanca",{"id":147,"slug":148,"hasResults":12,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":18,"sex":19,"minAge":61,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":157,"phases":4,"briefSummary":158,"conditions":159,"keywords":161,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":172},"100639760","protective-effect-of-lactation-against-gestational-diabetes-mellitus-in-subsequent-pregnancies-a-prospective-observational-cohort-study-100639760","NCT07624968","Protective Effect of Lactation Against Gestational Diabetes Mellitus in Subsequent Pregnancies: A Prospective Observational Cohort Study","Protective Effect of Lactation Against Gestational Diabetes Mellitus in Subsequent Pregnancy: A Prospective Observational Cohort Study","LACGDM","Inclusion Criteria:\n\n* Pregnant individuals aged 18 to 50 years.\n* Singleton pregnancy.\n* Conception during the lactation period.\n* Follow-up at Prof. Dr. Cemil Taşcıoğlu City Hospital or Esenyurt Necmi Kadıoğlu State Hospital.\n* Availability of glycemic parameters including fasting plasma glucose, HbA1c, glycosuria, and 75-g oral glucose tolerance test (OGTT) results.\n* Availability of routine ultrasonographic measurements including fetal abdominal circumference percentile (AC), estimated fetal weight percentile (EFW), and amniotic fluid index (AFI).\n\nExclusion Criteria:\n\n* Age below 18 years.\n* Age above 50 years.\n* Multiple pregnancy.\n* Known chronic systemic disease or pre-existing diabetes mellitus.\n* Missing clinical, laboratory, or ultrasonographic data.","50 Years",{"count":156,"type":23},140,"OBSERVATIONAL","Gestational diabetes mellitus (GDM) is a common metabolic disorder of pregnancy associated with increased maternal and fetal morbidity. Lactation has been suggested to improve maternal glucose metabolism, enhance insulin sensitivity, and reduce the risk of future glucose intolerance. However, evidence regarding the protective effect of lactation on the development of GDM in subsequent pregnancies remains limited.\n\nThis prospective observational cohort study aims to evaluate the association between lactation and the risk of gestational diabetes mellitus and related pregnancy complications in women who conceive during the lactation period. Routine glycemic markers including fasting plasma glucose, HbA1c, glycosuria, and 75-g oral glucose tolerance test (OGTT) results will be recorded. Ultrasonographic findings including fetal abdominal circumference percentile, estimated fetal weight percentile, and amniotic fluid index will also be assessed. The study will investigate whether lactation is associated with a reduced risk of GDM, fetal macrosomia, and polyhydramnios in subsequent pregnancies.",[29,160],"Lactating Mother",[162],"Gestational Diabetes Mellitus,Lactation,Breastfeeding,Glucose Metabolism,Maternal Health","2026-05-29",{"date":165,"type":47},"2026-06-03",{"date":167,"type":47},"2026-01-15",{"date":169,"type":23},"2027-12-31",{"name":171,"class":54},"Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization",2,{"id":174,"slug":175,"hasResults":12,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":12,"sex":19,"minAge":61,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":24,"phases":183,"briefSummary":184,"conditions":185,"keywords":186,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":114},"100621611","feasibility-testing-of-the-myglucocare-smartphone-app-for-women-with-gestational-diabetes-100621611","NCT07372872","Feasibility Testing of the \"MyGlucoCare\" Smartphone App for Women With Gestational Diabetes","Development and Feasibility Testing of the \"MyGlucoCare\" Smartphone-Based Self-Management for Personalised Support of Women With Gestational Diabetes","MyGlucoCare","Inclusion Criteria:\n\n* Pregnant women diagnosed with Gestational Diabetes Mellitus (GDM) via a 75g Oral Glucose Tolerance Test (OGTT), conducted between 24 and 28 weeks of gestation (Hong Kong College of Obstetricians and Gynaecologists, 2016).\n* Aged 18 years or older.\n* Own a smartphone with reliable internet access.\n* Able to read and understand Chinese.\n\nExclusion Criteria:\n\n* Pre-existing diagnosis of Type 1 or Type 2 diabetes mellitus.\n* Known major fetal anomaly.\n* Concurrent enrollment in any other structured GDM self-management intervention.\n* Severe mental health conditions.",{"count":182,"type":23},30,[26],"The goal of this pilot study is to test the feasibility and preliminary impact of \"MyGlucoCare,\" a smartphone-based program designed to support women with gestational diabetes (GDM). The main questions it aims to answer are:\n\nIs the \"MyGlucoCare\" program practical and acceptable for participants?\n\nDoes it show preliminary signs of improving self-management, blood sugar control, and well-being in women with gestational diabetes (GDM)?\n\nResearchers will conduct a single-arm study to gather initial data on the program's use and effects, which will be used to plan a larger future clinical trial.\n\nParticipants will:\n\nUse the \"MyGlucoCare\" app for 8-12 weeks during their pregnancy.\n\nReceive personalized education, support from a clinician, and access to a moderated peer group through the app.\n\nComplete questionnaires and log health data via the app at the start, near the end of pregnancy, and after giving birth.\n\nSome participants will also take part in an interview to share their feedback on the program.",[29],[89,187,188],"Smartphone-Based Self-Management","Personalised Support","2026-05-19",{"date":191,"type":47},"2026-05-22",{"date":193,"type":47},"2026-05-01",{"date":195,"type":23},"2026-11-30",{"name":197,"class":54},"Hong Kong Metropolitan University",{"id":199,"slug":200,"hasResults":12,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":12,"sex":19,"minAge":61,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":24,"phases":207,"briefSummary":208,"conditions":209,"keywords":210,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":114},"100635869","continuous-glucose-monitoring-versus-self-monitoring-of-blood-glucose-in-women-with-gestational-diabetes-100635869","NCT07558291","Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Women With Gestational Diabetes","Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Women With Gestational Diabetes: A Pilot Randomized Clinical Trial","Inclusion Criteria:\n\n* Pregnant women aged ≥18 years\n* Singleton pregnancy\n* Diagnosis of gestational diabetes mellitus (GDM) according to local two-step protocol (abnormal 50 g glucose challenge test followed by abnormal 100 g oral glucose tolerance test with at least 2 abnormal values)\n* Gestational age between 24 and 28 weeks at time of GDM diagnosis\n* Access to a compatible smartphone or digital device with internet connection to allow synchronization and remote upload of glucose data (CGM or SMBG)\n* Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Preexisting type 1 or type 2 diabetes mellitus\n* History of bariatric surgery\n* Treatment with metformin during pregnancy\n* Chronic systemic corticosteroid therapy\n* Known contraindications to use of a CGM sensor (e.g., severe dermatologic conditions at insertion site)\n* Inability to comply with study procedures or follow-up",{"count":206,"type":23},100,[26],"Gestational diabetes mellitus (GDM) is a type of diabetes that is first diagnosed during pregnancy. It causes high blood sugar levels and can increase the risk of health problems for both the mother and the baby. Babies may grow larger than expected (macrosomia), which can make delivery more difficult and increase the risk of birth complications. Mothers with GDM are also more likely to need insulin treatment and may have a higher risk of high blood pressure during pregnancy. Good blood sugar control is important to reduce these risks.\n\nThe usual way to monitor blood sugar in women with GDM is by self-monitoring of blood glucose (SMBG). This involves pricking the finger several times a day to measure blood sugar levels. Although this method provides useful information, it only shows glucose levels at specific moments and may miss changes that happen during the night or between measurements.\n\nContinuous glucose monitoring (CGM) is a newer method that uses a small sensor placed under the skin to measure glucose levels throughout the day and night. It provides more detailed information about blood sugar patterns and does not require frequent finger pricks. CGM has been shown to improve blood sugar control in people with type 1 and type 2 diabetes, but its benefits in women with gestational diabetes are not yet fully known.\n\nThe purpose of this study is to compare continuous glucose monitoring (CGM) with standard finger-prick monitoring (SMBG) in pregnant women diagnosed with gestational diabetes between 24 and 28 weeks of pregnancy. The study will evaluate whether CGM is practical to use, whether women are satisfied with it, and whether it may help improve blood sugar control and pregnancy outcomes.\n\nA total of 100 pregnant women with gestational diabetes will take part in this study. Participants will be randomly assigned (like flipping a coin) to one of two groups:\n\nOne group will use a continuous glucose monitoring device.\n\nThe other group will continue with standard finger-prick blood glucose monitoring.\n\nBoth groups will receive the same medical care, including dietary advice, physical activity recommendations, and insulin treatment if needed. Participants will attend regular pregnancy visits every 2 to 3 weeks until delivery, as part of usual care. No extra hospital visits are required because of the study. Women using CGM will receive training on how to use the device.\n\nThe researchers will compare blood sugar control, the need for insulin, pregnancy complications, and newborn outcomes such as birth weight and episodes of low blood sugar after birth. The study will also assess how satisfied women are with their glucose monitoring method and how it affects their quality of life.\n\nThis is a pilot study, which means its main goal is to determine whether a larger study should be carried out in the future. The results will help researchers understand whether continuous glucose monitoring could improve the care of women with gestational diabetes and their babies.",[29],[211,212,213,214,215],"Gestational Diabetes Mellitus","Continuous Glucose Monitoring","Glycemic Control","Patient-Reported Outcomes","Self-Monitoring of Blood Glucose","2026-05-12",{"date":218,"type":47},"2026-05-14",{"date":220,"type":23},"2026-07-01",{"date":222,"type":23},"2027-05-31",{"name":224,"class":54},"Hospital Clinic of Barcelona",{"id":226,"slug":227,"hasResults":12,"nctId":228,"briefTitle":229,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":12,"sex":19,"minAge":61,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":24,"phases":234,"briefSummary":235,"conditions":236,"keywords":238,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":114},"100638328","natural-cervical-ripening-to-prevent-pharmacological-induction-of-labor---a-pilot-study-100638328","NCT07587632","Natural Cervical Ripening to Prevent Pharmacological Induction of Labor - a Pilot Study.","Cervinat","Inclusion Criteria:\n\n* Singleton gestation\n* Non-insulin dependent, dietetically managed gestational diabetes\n* Greater than or equal to 34 weeks.\n* Planned vaginal birth at the University Hospital of Zurich\n* Planned IOL for 40 weeks of gestation.\n* Communication in German and\u002For English language possible.\n\nExclusion Criteria:\n\n* Pregnant women with multiple gestation\n* Fetal macrosomia \\>95th percentile\n* Intrauterine growth restriction \\\u003C3rd percentile\n* Already in labor (regular contractions or premature rupture of membranes (PROM)\n* Patients scheduled for IOL before 40 weeks\n* Insulin-dependent diabetes\n* Planned cesarean section\n* Planned birth in an external hospital\n* Inability to follow the procedures e.g. due to language problems, psychological disorders",{"count":233,"type":23},74,[26],"As of today, around 25% of all vaginal births happen after induction of labor (IOL). The internal guidelines of the University Hospital Zurich currently recommend pregnant women with a non-insulin dependent gestational diabetes an IOL around term. One possibility to prevent an IOL and increase the chance for a spontaneous onset of birth is a ripening of the cervix by alternative methods in an outpatient setting. The primary objective of this study is to evaluate the effect of natural cervical ripening methods on the time interval between 37 weeks (beginning of the intervention) and the onset of spontaneous labor.",[36,237,29],"Induction of Labor",[239,240,241,242,243,244],"gestational Diabetes","Induction of labor","cervical ripening","pregnancy","colostrum banking","membrane sweeping","2026-05-07",{"date":218,"type":47},{"date":248,"type":47},"2026-04-10",{"date":250,"type":23},"2029-12-31",{"name":252,"class":54},"University of Zurich",{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":259,"eligibilityCriteria":260,"healthyVolunteers":12,"sex":19,"minAge":61,"maxAge":261,"enrollmentInfo":262,"targetDuration":263,"studyType":157,"phases":4,"briefSummary":264,"conditions":265,"keywords":274,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":114},"100636441","cardiometabolic-disease-and-substrate-metabolism-100636441","NCT07565727","Cardiometabolic Disease and Substrate Metabolism","Cardiometabolic Disease, Substrate Metabolism, and Abnormal Placental Pathology: a Multimodal Maternal-Fetal Study","CAP","Inclusion Criteria:\n\n* Age 18-45\n* Any pre-pregnancy BMI\n* At least one high risk OR one moderate risk factor for pre-eclampsia based on ACOG and USPSTF guidelines\n* Willingness to adhere to aspirin therapy\n* Willingness to undergo 2h OGTT for serum collection in addition to survey collection, indirect calorimetry, body composition measures, neonatal measures, etc.\n* Gestational age at enrollment \\\u003C18 weeks\n* Ability to speak, read, and communicate via English\n\nExclusion Criteria:\n\n* Type 2 Diabetes Mellitus\n* Type 1 Diabetes Mellitus\n* Current gestational diabetes mellitus\n* Current\u002Factive platelet disorder or bleeding diathesis (thrombocytopenia of any etiology, idiopathic thrombocytopenic purpura\u002FITP, thrombotic thrombocytopenic purpura\u002FTTP, von Willebrand disease, etc.)\n* Thrombophilia\n* Current use of NSAID for other indication (indomethacin, ibuprofen, etc.)\n* Current use of other immune-modulating agents and biologics (hydroxychloroquine, azathioprine, 6-mercaptopurine, IL-6 inhibitors, etc.)\n* Current or recent use of steroids\n* Current use of prophylactic or therapeutic anticoagulation\n* Medical contraindication to aspirin therapy\n* Molar pregnancy\n* Renal disease\n* Inability or unwillingness to give informed consent\n* Current psychiatric illness\u002Fsocial situation that would limit compliance with study requirements, as determined by the principal investigators","45 Years",{"count":63,"type":23},"9 Months","This study's primary purpose is to determine the potential relationship between cardiometabolic disease, specifically insulin resistance (HOMA-IR), and maternal lipid oxidation.",[127,29,266,267,268,269,270,271,272,36,98,273],"Preeclampsia (PE)","Preeclampsia (PE) Risk","Gestational Diabetes","Gestational Diabetes Mellitus in Pregnancy","Cardiometabolic Diseases","Insulin Resistance","Placental Dysfunction","Gestational Complications",[275,276,127,268,277,278,279,280,281],"Cardiometabolic disease","Substrate metabolism","Insulin resistance","HOMA-IR","Lipid oxidation","Placental dysfunction","Chorangiosis","2026-04-27",{"date":284,"type":47},"2026-05-04",{"date":286,"type":47},"2025-12-10",{"date":288,"type":23},"2027-08",{"name":290,"class":54},"University of Tennessee Graduate School of Medicine",{"id":292,"slug":293,"hasResults":12,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":297,"eligibilityCriteria":298,"healthyVolunteers":12,"sex":19,"minAge":61,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":24,"phases":301,"briefSummary":302,"conditions":303,"keywords":312,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":4},"100635983","the-root-study-scaling-the-standard-of-care-plus-obstetric-nutrition-model-to-optimize-maternal-and-infant-health-100635983","NCT07559773","The ROOT Study: Scaling the 'Standard of Care Plus' Obstetric Nutrition Model to Optimize Maternal and Infant Health","The ROOT Study: Scaling the 'Standard of Care Plus' Obstetric Nutrition Integrated Model to Optimize Maternal and Infant Health: a Prospective Interventional Study: Resilient Outcomes Through OB-Nutrition Team Care (ROOT)","ROOT","Inclusion Criteria:\n\n* Pregnant women receiving care at NH Triad OB\u002FGYN\n* ≤20 weeks gestational age at enrollment\n* Age ≥ 18 years (\\\u003C18 years requires parental consent)\n* Ability to provide informed consent\n* Access to smart phone\u002Finternet for digital platform use\n\nExclusion Criteria:\n\n* \\> 20 weeks gestational age\n* High-risk pregnancies requiring specialized care beyond study scope\n* Inability to participate in digital health platform\n* Cognitive impairment preventing informed consent",{"count":300,"type":23},500,[26],"The 'Standard of Care Plus' ('PLUS') model in the ROOT Study consists of analyzing select micronutrient and gene variants of pregnant females to construct trimester-specific and personalized nutrition and lifestyle recommendations in collaboration with in-person standard obstetric care (SOC).\n\nIn 2014, the investigators demonstrated statistically significant reductions in adverse maternal and infant outcomes using the 'PLUS' model compared to SOC alone. Further study in a 50% Medicaid Oregon 'PLUS' cohort (N=387) demonstrated association with highly significant risk reductions in all primary outcomes (p-value \\\u003C0.001): preterm birth: relative risk (RR) = 0.238 (4.2x less likely), hypertensive disorders of pregnancy: RR = 0.229 (4.4x less likely), gestational diabetes: RR = 0.071 (14x less likely), small for gestational age: RR = 0.252 (4x less likely), and large for gestational age: RR = 0.357 (2.8x less likely). A 100% Medicaid and ethnically diverse Nevada 'PLUS' cohort showed similar trends in all outcomes that were not statistically significant because of small sample size.\n\nStructured as a prospective interventional study, the study evaluates whether the 'PLUS' model can achieve similar outcome improvements within the Novant Health (NH) system in North Carolina. The study will assess both clinical outcomes and digital nutrition platform performance within the existing healthcare infrastructure.\n\nThe primary hypothesis of the ROOT study is that collaborative implementation of the 'PLUS' nutritional care model at NH Triad Obstetrics\u002FGynecology (OB\u002FGYN) Clinic will be associated with reduced maternal and infant adverse outcome rates when compared to historical regional and NH system outcomes in those who received SOC alone.\n\nThe secondary hypothesis of the ROOT Study is that the 'PLUS' model applied during pregnancy will be associated with reduced pediatric adverse outcomes. The 'PLUS' offspring that remain in the NH system will be observed longitudinally over 5 years with chart review at birth through 2 weeks of age, and at 1, 3, and 5 years of life. The outcomes assessed include neonatal intensive care unit (NICU) admission in the first two weeks of life, atopic dermatitis, eczema, asthma, allergies, otitis media, obesity, and autism. The 'PLUS' adverse outcome rates will be compared to adverse outcome rates in children born regionally and nationally under SOC alone.\n\nParticipant compliance with the 'PLUS' model, and participant and nutritionist access to the digital health platform will be studied during each trimester of use, as well as in the postpartum time period. The exploratory hypothesis is that the digital platform will not affect access, compliance, and rates of maternal and neonatal adverse outcomes.",[304,127,29,305,306,307,308,309,310,311],"Preterm Birth","Small for Gestational Age (SGA)","Large for Gestational Age (LGA)","Asthma Childhood","Atopic Dermatitis","Autism","Otitis Media Recurrent","Obesity",[313,314,315,316,317,318,319,320,321,322],"adverse pregnancy outcomes","prevention","personalized nutrition","nutrigenomics","adverse neonatal outcomes","childhood asthma","childhood allergy","autism","childhood obesity","recurrent otitis media",{"date":324,"type":47},"2026-04-30",{"date":326,"type":23},"2026-08",{"date":328,"type":23},"2033-12",{"name":330,"class":54},"GrowBaby Life Project",{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":24,"phases":340,"briefSummary":341,"conditions":342,"keywords":343,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":348,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":114},"100630575","screening-for-dysglycemia-during-postpartum-period-in-women-with-gdm-100630575","NCT07489456","Screening for Dysglycemia During Postpartum Period in Women With GDM","Strategies for Improving the Detection of Dysglycemia in the Postpartum Period in Women With Gestational Diabetes: Electronic Reminders and New Diagnostic Criteria","Inclusion Criteria:\n\n* Diagnosis of gestational diabetes mellitus, according to diagnostic criteria proposed by the IADPSG, namely:\n* initial fasting blood glucose ≥ 92mg\u002FdL OR\n* 75g oral glucose tolerance test with fasting ≥ 92mg\u002FdL or after 1h ≥ 180mg\u002FdL or after 2h ≥ 153mg\u002FdL Delivery performed at HC-FMUSP Scheduling of the 75g oral glucose tolerance test between 6 and 12 weeks after delivery Agreement with the informed consent form\n\nExclusion Criteria:\n\nWithdrawal of consent Failure to complete the TOTG exam due to vomiting (exclusion from analysis 2 only)",{"count":339,"type":23},182,[26],"Gestational diabetes mellitus (GDM) is one of the most common clinical conditions in pregnancy, with an increasing incidence due to the rise in overweight women and the postponement of motherhood. It is associated with perinatal complications and an increased risk of developing prediabetes and type 2 diabetes after delivery. Therefore, it is recommended that a 75g oral glucose tolerance test (OGTT-75g) be performed between 6 and 12 weeks postpartum. Despite its relevance, the rate of adherence to the test is low. Recent studies also indicate that measuring blood glucose one hour after the overload may be more sensitive than the traditional two-hour measurement in the early detection of dysglycemia. This study aims to evaluate strategies for qualifying the screening of metabolic changes in the postpartum period among women with GDM. The objectives are: (1) to analyze the impact of sending reminders via WhatsApp on the attendance rate for the 75g OGTT; and (2) to compare the frequency of prediabetes and diabetes diagnoses using two different diagnostic strategies applied to the same test-the traditional (fasting and 2-hour blood glucose) and the alternative (fasting and 1-hour blood glucose).",[29],[344,103,345,346,347],"dysglycemia","prediabetes","diabetes","postpartum OGTT",{"date":284,"type":47},{"date":350,"type":47},"2026-03-24",{"date":352,"type":23},"2026-11",{"name":354,"class":54},"University of Sao Paulo General Hospital",{"id":356,"slug":357,"hasResults":12,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":361,"eligibilityCriteria":362,"healthyVolunteers":12,"sex":19,"minAge":61,"maxAge":154,"enrollmentInfo":363,"targetDuration":4,"studyType":24,"phases":365,"briefSummary":366,"conditions":367,"keywords":368,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":114},"100585010","determining-the-effect-of-food-ordering-on-blood-glucose-in-gestational-diabetes-mellitus-defi-gdm-100585010","NCT06896799","Determining the Effect of Food Ordering on Blood Glucose In Gestational Diabetes Mellitus (DEFI-GDM)","Determining the Effect of Food Ordering on Blood Glucose In Gestational Diabetes Mellitus (DEFI-GDM) - a Randomised Crossover Study","DEFI-GDM","Inclusion Criteria:\n\n* Pregnant women with gestational diabetes mellitus\n* Aged 18-50 years old\n\nExclusion Criteria:\n\n* History of type 1 or type 2 diabetes mellitus\n* Dietary restrictions or clinically confirmed food allergies that may affect study requirements\n* Pharmacologically managed GDM at the point of study entry\n* Hyperemesis gravidarum at the point of study entry (i.e. prolonged\u002Fsevere nausea and vomiting)\n* Using antiemetic medication (e.g. dimenhydrinate, prochlorperazine, promethazine)\n* Any other problems or medical conditions that would substantially limit their ability to complete the study requirements\n\nParticipants can be recruited onto the study if they have previously had GDM in another pregnancy. Participants can also be recruited if they are involved in other research studies, but this will depend on the study type and the decision will be made by the Chief\u002FPrincipal Investigator.",{"count":364,"type":23},35,[26],"The goal of this clinical trial is to determine whether the sequence of macronutrient consumption affects post-prandial glycaemia in women with gestational diabetes mellitus.\n\nThe main questions it aims to answer are:\n\n* The difference in the magnitude of postprandial rise in blood glucose between the two test meals.\n* The difference in the magnitude of postprandial change in serum levels of gut hormones between the two test meals.\n* The difference in mean change in pre-post ingestion satiety scores between the two test meals.\n* The difference in 24 hour energy and macronutrient intake following the two test meals.\n\nParticipants will attend two study visits at the Centre for Public Health, with an interval of at least two days between the visits and complete the following, anthropometric measurements, demographic and appetite questionnaires, glucose measurements, two food diaries and fasting blood samples and the consumption of the study breakfast. Participants will be asked to eat either the protein\u002Ffat-based component of the meal (scrambled egg) before or after the carbohydrate-based component (wholemeal toast) on their first visit and on the other visit they will be asked to eat the meal in the reverse order. The order in which this occurs will be randomised and each participant will act as their own control. Researchers will compare the results from participants between the two test meals to see if the order of macronutrient consumption has any effect on post-prandial glycaemia, gut hormones, satiety scores and energy and macronutrient intake.",[29],[211,369,370],"Post-prandial glycaemia","Food Ordering","2026-04-14",{"date":373,"type":47},"2026-04-17",{"date":375,"type":47},"2025-12-11",{"date":377,"type":23},"2027-02-01",{"name":379,"class":54},"Queen's University, Belfast",{"id":381,"slug":382,"hasResults":12,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":386,"eligibilityCriteria":387,"healthyVolunteers":12,"sex":19,"minAge":61,"maxAge":4,"enrollmentInfo":388,"targetDuration":4,"studyType":157,"phases":4,"briefSummary":390,"conditions":391,"keywords":392,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":114},"100628305","gestational-diabetes-and-health-outcomes-in-mothers-and-babies-100628305","NCT07459907","Gestational Diabetes and Health Outcomes in Mothers and Babies","Understanding the Effects of Gestational Diabetes on Mother and Baby","GRAZ-GDM","Inclusion Criteria:\n\n* ongoing pregnancy prior to the 32nd gestational week and a positive GDM screening\n\nExclusion Criteria:\n\n* gestational age 32nd gestational week\n* fetal genetic anomalies \u002Fmalformation",{"count":389,"type":23},400,"Gestational diabetes mellitus (GDM) is a common pregnancy complication characterized by impaired glucose metabolism and increased insulin resistance. GDM is associated with adverse pregnancy outcomes and an increased long-term risk of metabolic and cardiovascular disease for both mother and offspring.\n\nThis prospective observational cohort study aims to establish a longitudinal pregnancy and birth cohort of women diagnosed with GDM. Pregnant women with a positive 75 g oral glucose tolerance test (OGTT) between gestational weeks 24 and 28 will be recruited after diagnosis and followed through late pregnancy, delivery, and early postpartum.\n\nParticipants will undergo two study visits during pregnancy, sample collection at delivery, and one postpartum visit 8-12 weeks after birth. Clinical data, physical measurements, questionnaire-based information, and biological samples will be collected from mothers and infants to enable comprehensive phenotyping of GDM pregnancies.\n\nData and biosamples from this cohort will be used for descriptive and hypothesis-driven analyses and may be compared with data from an existing longitudinal cohort of healthy pregnancies to support interpretation of GDM-related changes.",[29,36],[89,277,393,394,395,396,397,36,398,399,400,401],"Glucose metabolism","Cardiometabolic risk","Pregnancy outcomes","Pregnancy phenotyping","Maternal and infant health","Post-partum follow up","Longitudinal cohort","Fetal growth","Neonatal adiposity","2026-04-09",{"date":404,"type":47},"2026-04-13",{"date":406,"type":47},"2025-06-15",{"date":408,"type":23},"2035-06",{"name":410,"class":54},"Medical University of Graz",{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":417,"eligibilityCriteria":418,"healthyVolunteers":12,"sex":19,"minAge":61,"maxAge":154,"enrollmentInfo":419,"targetDuration":263,"studyType":157,"phases":4,"briefSummary":421,"conditions":422,"keywords":424,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":432,"completionDateStruct":434,"leadSponsor":436,"locationsCount":114},"100632724","glycemic-markers-for-predicting-gestational-diabetes-in-pregnant-women-with-previous-bariatric-surgery-100632724","NCT07517406","Glycemic Markers for Predicting Gestational Diabetes in Pregnant Women With Previous Bariatric Surgery","Predictive Value of Glycemic Markers for Gestational Diabetes Mellitus and Pregnancy Complications in Pregnant Women With Prior Bariatric Surgery Who Cannot Tolerate Oral Glucose Tolerance Testing","BARI-GDM","Inclusion Criteria\n\n* Pregnant women aged 18-50 years\n* Singleton pregnancy\n* History of bariatric surgery prior to pregnancy\n* Followed at Prof. Dr. Cemil Taşcıoğlu City Hospital, Department of Obstetrics and Gynecology\n* Availability of glycemic parameters during early pregnancy (≤14 weeks) and\u002For between 24 and 28 weeks of gestation (fasting plasma glucose, HbA1c, urine glucose, and\u002For OGTT results if tolerated)\n* Availability of sonographic and clinical follow-up data between 28 weeks of gestation and delivery (up to 40 weeks) Exclusion Criteria\n* Age \\\u003C18 years or \\>50 years\n* Multiple pregnancy\n* Presence of known chronic systemic disease (e.g., pregestational diabetes or endocrine disorders)\n* Incomplete or missing clinical data",{"count":420,"type":23},84,"Gestational diabetes mellitus (GDM) is associated with significant maternal and fetal complications. The standard diagnostic test for GDM is the 75-gram oral glucose tolerance test (OGTT). However, pregnant women who have undergone bariatric surgery may not tolerate OGTT due to dumping syndrome and gastrointestinal side effects. This creates diagnostic challenges in this specific population.\n\nThe aim of this prospective observational study is to evaluate whether routinely measured glycemic markers, including fasting blood glucose, postprandial blood glucose, HbA1c, and urinary glucose levels, can predict the development of gestational diabetes mellitus and related pregnancy complications in women with prior bariatric surgery.\n\nPregnant women aged 18-50 years with a history of bariatric surgery will be enrolled and followed throughout pregnancy. The predictive value of glycemic markers for GDM, macrosomia, and polyhydramnios will be analyzed using multivariable logistic regression models.\n\nThis study aims to provide alternative diagnostic approaches for GDM screening in pregnant women who are unable to tolerate OGTT and to contribute to improving maternal and perinatal outcomes in this growing patient population.",[29,98,423],"History of Bariatric Surgery",[211,425,426,427,428],"Bariatric Surgery","Glucose Intolerance","Glycemic Markers","Oral Glucose Tolerance Test","2026-04-01",{"date":431,"type":47},"2026-04-08",{"date":433,"type":47},"2026-02-01",{"date":435,"type":23},"2027-12",{"name":437,"class":54},"Burak Deniz Aydoğdu",{"id":439,"slug":440,"hasResults":12,"nctId":441,"briefTitle":442,"officialTitle":443,"acronym":4,"eligibilityCriteria":444,"healthyVolunteers":18,"sex":445,"minAge":61,"maxAge":4,"enrollmentInfo":446,"targetDuration":4,"studyType":157,"phases":4,"briefSummary":448,"conditions":449,"keywords":453,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":459,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":464,"locationsCount":114},"100606533","pregnancy-and-postpartum-breastfeeding-support-for-patients-with-gestational-diabetes-100606533","NCT07176793","Pregnancy and Postpartum Breastfeeding Support for Patients With Gestational Diabetes","Preventing Type 2 Diabetes Following Gestational Diabetes: Implementation Mapping for a Multilevel Breastfeeding Support Strategy","Inclusion Criteria:\n\n* ≥18 years old and able to communicate in English\n* Fits into one of the following:\n\n  1. patients with GDM who are recently pregnant and\u002For postpartum;\n  2. health care providers (nurses, physicians, lactation consultants, etc.) who would implement the strategy\n  3. executive leadership\n\nExclusion Criteria:\n\n* Subjects not meeting the inclusion criteria will be considered ineligible for participation","ALL",{"count":447,"type":23},10,"The investigators will use implementation methods to develop better breastfeeding support for patients with gestational diabetes as a way to prevent type 2 diabetes.",[29,450,451,452],"Diabetes Type 2","Breastfeeding Continuation","Breastfeeding Support",[268,454,455,456,457,458],"Preventing Diabetes Type 2 after GDM","Breastfeeding","Focus Groups","Implementation mapping","Breastfeeding support strategy",{"date":460,"type":47},"2026-04-07",{"date":462,"type":47},"2026-03-23",{"date":44,"type":23},{"name":465,"class":54},"University of California, Davis",{"id":467,"slug":468,"hasResults":12,"nctId":469,"briefTitle":470,"officialTitle":470,"acronym":471,"eligibilityCriteria":472,"healthyVolunteers":18,"sex":445,"minAge":61,"maxAge":4,"enrollmentInfo":473,"targetDuration":4,"studyType":157,"phases":4,"briefSummary":475,"conditions":476,"keywords":477,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":114},"100626481","imprinting-in-metabolic-diseases---identifying-epigenetic-mechanisms-in-human-gestational-diabetes-through-cell-free-dna-100626481","NCT07436195","Imprinting in Metabolic Diseases - Identifying Epigenetic Mechanisms in Human Gestational Diabetes Through Cell-free DNA","Epi_GDM","Inclusion Criteria:\n\n* Pregnant women between 20 and 28 weeks of gestation\n* The father of the child is known and willing to participate in the study\n* No known underlying medical conditions in either parent\n* No fetal abnormalities detected in first-trimester screening, detailed fetal anatomy ultrasound, non-invasive prenatal testing (NIPT), or any additional prenatal examinations performed, if applicable\n* No known underlying diseases\n* Understanding and voluntary signing of a consent form before study- related examinations\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Type 1 or type 2 diabetes mellitus\n* Pharmacological treatment affecting blood glucose levels (e.g., steroids, insulin)\n* Endocrine disorders (e.g., hyperthyroidism, polycystic ovary syndrome \\[PCOS\\])\n* Current depression or other psychiatric disorders\n* Eating disorders\n* Regular use of medication during pregnancy\n* Pre-existing cardiovascular disease\n* Drug and\u002For alcohol abuse\n* Estimated glomerular filtration rate (eGFR) \\\u003C 60 ml\u002Fmin\u002F1.73 m²\n* C-reactive protein \\> 10 mg\u002Fl\n* Transaminase elevation of 2 times the upper norm\n* No consent to be informed about incidentally discovered pathological findings\n* Any other (clinical) condition that would endanger participants safety or question scientific success according to the physicians opinion.",{"count":474,"type":23},80,"This clinical trials aims to investigate the impact of parental metabolism during pregnancy on fetal epigenetic signatures.\n\nThe metabolic profiles of both parents will be evaluated through a blood sample collected from the father and an oral glucose tolerance test administered to the pregnant mother. Additionally, epigenetic signatures will be assessed using parental blood samples. Fetal epigenetic signatures can be identified by analyzing fetal cell-free DNA that circulates in the mother's bloodstream.",[29],[478,242,479,480,103],"epigenetics","parental metabolism","Cell-free DNA","2026-03-31",{"date":460,"type":47},{"date":484,"type":47},"2026-03-30",{"date":486,"type":23},"2028-07-01",{"name":488,"class":54},"University of Ulm",{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":4,"eligibilityCriteria":495,"healthyVolunteers":12,"sex":19,"minAge":61,"maxAge":4,"enrollmentInfo":496,"targetDuration":4,"studyType":24,"phases":498,"briefSummary":499,"conditions":500,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":501,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":506,"locationsCount":172},"100631357","digital-health-intervention-for-early-identification-and-prevention-of-gestational-diabetes-mellitus-100631357","NCT07499622","Digital Health Intervention for Early Identification and Prevention of Gestational Diabetes Mellitus","A Multicenter Randomized Controlled Trial of a Digital Health Intervention for Risk Identification, Intelligent Early Warning, and Prevention of Gestational Diabetes Mellitus Based on Multi-Source Data Integration","Inclusion Criteria:\n\n* Pregnant women in early pregnancy (within 13 weeks and 6 days of gestation)\n* Planned delivery at a participating study hospital\n* Age 18 years or older\n* Singleton pregnancy\n* Identified as high risk for gestational diabetes mellitus by the study risk assessment model\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* • Pre-pregnancy diabetes mellitus or overt diabetes diagnosed at the first antenatal visit (fasting blood glucose greater than or equal to 7.0 mmol\u002FL)\n\n  * Pre-existing hypertension, autoimmune disease, major infection, or severe liver or kidney disease\n  * Use of medications that affect glucose metabolism, such as corticosteroids or metformin\n  * Severe psychiatric disorders\n  * Inability or unwillingness to comply with study procedures",{"count":497,"type":23},1200,[26],"This study aims to develop and evaluate an early risk identification and digital health intervention strategy for gestational diabetes mellitus (GDM) among pregnant women in China. Gestational diabetes mellitus is a common pregnancy complication associated with adverse maternal and neonatal outcomes, including excessive gestational weight gain, macrosomia, cesarean delivery, and increased long-term risk of metabolic disorders in both mothers and offspring.\n\nThe study includes two components. First, retrospective multi-source clinical data from maternal health records will be used to develop and validate a risk prediction model for early identification of pregnant women at high risk of GDM. Second, pregnant women identified as high risk in early pregnancy will be enrolled in a multicenter randomized controlled trial and assigned to either a digital health intervention group or a usual care group. The intervention includes online health education, individualized lifestyle guidance, behavioral self-management tools, and interactive consultation through a digital platform. The primary outcome is the incidence of GDM diagnosed during pregnancy. Secondary outcomes include gestational weight gain, cesarean delivery, macrosomia, and other maternal and neonatal outcomes.\n\nThis study is expected to provide evidence for improving early risk assessment, intelligent warning, and prevention strategies for GDM in the context of maternal health management in China.",[29],{"date":484,"type":47},{"date":503,"type":23},"2026-06",{"date":505,"type":23},"2028-12",{"name":507,"class":54},"Peking University",{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":512,"acronym":4,"eligibilityCriteria":513,"healthyVolunteers":18,"sex":19,"minAge":61,"maxAge":4,"enrollmentInfo":514,"targetDuration":4,"studyType":157,"phases":4,"briefSummary":516,"conditions":517,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":523,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":529,"locationsCount":114},"100629105","placental-biology-in-health-and-disease-100629105","NCT07470320","Placental Biology in Health and Disease","Inclusion Criteria:\n\n* Female, aged 18 years or above\n* Willing and able to give informed consent for participation in the study\n* Able to read and understand written and spoken English to comprehend study materials and give informed consent\n* Non-pregnant women in good general health OR pregnant women who fall into one of the following:\n\n  * Healthy pregnancy\n  * Pre-eclampsia (PET) - defined by clinical diagnostic criteria, including hypertension and proteinuria\n  * Gestational diabetes mellitus (GDM) - diagnosed by standard glucose tolerance tests during pregnancy\n  * Fetal growth restriction (FGR) - diagnosed based on fetal weight or Doppler abnormalities\n  * Predisposed to PET - high-risk factors for PET such as maternal type 1 or type 2 diabetes, autoimmune diseases or multiple pregnancies\n\nExclusion Criteria:\n\n* Non-pregnant participants with active health conditions that could confound study outcomes\n* Pregnant participants with conditions unrelated to PET, GDM or FGR that could influence EV profiles e.g. active infections or malignancies",{"count":515,"type":23},360,"Pre-eclampsia (PET) is a condition characterised by high blood pressure and damage to other organs, and is a leading cause of maternal and fetal complications such as fetal growth restriction (FGR). Gestational diabetes mellitus (GDM) involves abnormal blood sugar levels during pregnancy and can have both short and long-term impacts on the health of the mother and child. Both conditions are linked to placental dysfunction but the precise mechanisms behind these links remain unclear.\n\nA major focus of this study is on extracellular vesicles (EVs) which are tiny, bubble-like particles released by the placenta into the mother's and baby's bloodstreams. These EVs act as messengers, carrying proteins, lipids and genetic material that can influence how cells function, even in parts of the body far from the placenta. Notably, the number and content of these EVs change in conditions like PET and GDM, suggesting they may play a role in the development of these complications.\n\nThis single-site, observational, laboratory study aims to investigate how these EVs contribute to maternal health and disease. To enable analysis across different physiological and pathological conditions pregnant participants with healthy pregnancies, pregnancies predisposed to PET and pregnancies complicated by GDM, FGR and PET will be recruited alongside healthy non-pregnant controls. Recruitment will be from the Oxford University Hospitals NHS Foundation Trust and the Nuffield Department of Women's and Reproductive Health, University of Oxford (who fund the research). Demographic and clinical data will be collected as well as blood, urine, breath, placenta, umbilical cord, umbilical cord blood, amniotic fluid and\u002For uterine vein blood samples.\n\nThrough examining EV content and function, it is hoped a better understanding of their role in pregnancy complications will be gained, including their potential as non-invasive biomarkers for early detection and targeted treatments, improving outcomes for mothers and babies worldwide.",[518,29,519,520,521,36],"Pre-eclampsia","Fetal Growth Restriction (FGR)","Pregnancy Induced Hypertension (PIH)","Placenta","2026-03-09",{"date":524,"type":47},"2026-03-13",{"date":526,"type":47},"2025-12-16",{"date":528,"type":23},"2030-05-31",{"name":530,"class":54},"University of Oxford",{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":537,"eligibilityCriteria":538,"healthyVolunteers":18,"sex":445,"minAge":539,"maxAge":540,"enrollmentInfo":541,"targetDuration":4,"studyType":24,"phases":543,"briefSummary":544,"conditions":545,"keywords":547,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":555,"completionDateStruct":557,"leadSponsor":558,"locationsCount":114},"100628527","continuous-glucose-monitoring-in-newborns-of-mothers-with-insulin-treated-gestational-diabetes-mellitus-100628527","NCT07462793","COntinuous Glucose Monitoring in nEwborns of Mothers With Insulin-Treated Gestational Diabetes Mellitus","COntinuous Glucose Monitoring in nEwborns of Mothers With Insulin-Treated Gestational Diabetes Mellitus (COMET-GDM): a Randomised Controlled Trial","COMET-GDM","Inclusion Criteria:\n\n* Maternal age of 18 years or older\n* Singleton pregnancy\n* Insulin-treated gestational diabetes mellitus\n\nExclusion Criteria:\n\n* Multifetal pregnancy\n* Congenital malformations or metabolic defects in the newborn\n* Preterm birth (defined as birth \\\u003C37 weeks of gestation)\n* Smoking during pregnancy\n* Preeclampsia, fetal growth restriction\n* Perinatal asphyxia\n* Congenital infections in the newborn\n* Adverse skin reactions (eczema, wounds) in the planned sensor insertion area","1 Minute","30 Minutes",{"count":542,"type":23},120,[26],"The purpose of this study is to determine whether continuous glucose monitoring (CGM) improves the detection and management of neonatal hypoglycaemia in newborns of mothers with insulin-treated gestational diabetes.",[546,29],"Neonatal Hypoglycemia",[548,549,550,551],"gestational diabetes mellitus","neonatal hypoglycemia","insulin-treated gestational diabetes","neurodevelopmental outcomes","2026-03-08",{"date":554,"type":47},"2026-03-10",{"date":556,"type":23},"2026-03",{"date":435,"type":23},{"name":559,"class":54},"Institute of Mother and Child, Warsaw, Poland",{"id":561,"slug":562,"hasResults":12,"nctId":563,"briefTitle":564,"officialTitle":565,"acronym":4,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":19,"minAge":61,"maxAge":4,"enrollmentInfo":567,"targetDuration":4,"studyType":24,"phases":569,"briefSummary":570,"conditions":571,"keywords":573,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":581,"leadSponsor":583,"locationsCount":83},"100592044","lifestyle-interventions-to-prevent-diabetes-in-us-home-visiting-programs-100592044","NCT06988306","Lifestyle Interventions to Prevent Diabetes in U.S. Home Visiting Programs","Randomized Controlled Trial of Lifestyle Interventions for the Prevention of Diabetes in US Home Visiting Programs","Inclusion Criteria:\n\n* Currently in home visiting\n* Pregnant or \\\u003C 3 months (13 weeks) postpartum\n* Gestational Diabetes Mellitus diagnosis in most recent pregnancy (based on self-report)\n* Aged 18 years or older\n* English- or Spanish-speaking.\n* Not currently being given medically tailored meals\n* Willing to receive randomization to either group\n\nExclusion Criteria:\n\n• Pre-existing diabetes (based on self-report)",{"count":568,"type":23},978,[26],"The study is examining the health effects of gestational diabetes mellitus (GDM) intervention and medically tailored meals within home visiting. A large study is proposed that will include nearly a thousand pregnant or recently pregnant adults with recent GDM and who are from different regions and backgrounds. Two treatment approaches are compared, and both are in home visiting. One treatment group is receiving enhanced lifestyle support for GDM along with meals, and the other is receiving just the enhanced lifestyle support. The study will examine whether these interventions help reduce diabetes and pre-diabetes through 12 months postpartum, as well as other health factors like weight and blood pressure.",[572,29],"Diabetes Mellitus",[574,103,575,576],"medically tailored meals","food is medicine","home visiting","2026-03-03",{"date":579,"type":47},"2026-03-05",{"date":167,"type":47},{"date":582,"type":23},"2030-04-30",{"name":584,"class":54},"California Polytechnic State University-San Luis Obispo",{"id":586,"slug":587,"hasResults":12,"nctId":588,"briefTitle":589,"officialTitle":590,"acronym":591,"eligibilityCriteria":592,"healthyVolunteers":18,"sex":19,"minAge":61,"maxAge":154,"enrollmentInfo":593,"targetDuration":4,"studyType":24,"phases":595,"briefSummary":596,"conditions":597,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":604,"locationsCount":172},"100582090","validating-cgm-for-gdm-100582090","NCT06858787","Validating CGM for GDM","The Validity of a Continuous Glucose Monitor in Diagnosing Gestational Diabetes: A Pilot Study","VALID","Inclusion Criteria:\n\n* Ages 18-50\n* Singleton pregnancy between 24-32 weeks gestational age\n* Prenatal care and delivery at Mount Sinai Hospital\n\nExclusion Criteria:\n\n* Multiple fetal gestation\n* Preexisting diabetes\n* Concurrent use of steroids\n* Anomalous fetus\n* Insufficient prenatal care (identified as missing half the recommended visits or establishing care after 20 weeks gestation)\n* Unable to tolerate oral glucose test",{"count":594,"type":23},150,[26],"This is a prospective pilot study to assess the validity of using a continuous glucose monitor (CGM) in diagnosing gestational diabetes mellitus (GDM). Pregnant individuals between the ages of 18-50 years old receiving prenatal care at Mount Sinai Hospital (e..g, E-Level clinic and Faculty Practice Associates) will be enrolled. Potential participants will be approached during their prenatal care appointments. Participants will complete an informed consent form for the study during their standard-of-care prenatal appointments at our institution.",[29],"2026-01-13",{"date":167,"type":47},{"date":601,"type":47},"2025-10-02",{"date":603,"type":23},"2028-04",{"name":605,"class":54},"Icahn School of Medicine at Mount Sinai",{"id":607,"slug":608,"hasResults":12,"nctId":609,"briefTitle":610,"officialTitle":610,"acronym":4,"eligibilityCriteria":611,"healthyVolunteers":18,"sex":19,"minAge":61,"maxAge":154,"enrollmentInfo":612,"targetDuration":4,"studyType":24,"phases":613,"briefSummary":615,"conditions":616,"keywords":619,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":622,"lastUpdatePostDateStruct":623,"startDateStruct":624,"completionDateStruct":626,"leadSponsor":628,"locationsCount":114},"100586130","phase-1-the-impact-of-gestational-diabetes-mellitus-on-cerebral-blood-flow-and-cerebrovascular-function-after-pregnancy-100586130","NCT06911372","The Impact of Gestational Diabetes Mellitus on Cerebral Blood Flow and Cerebrovascular Function After Pregnancy","INCLUSION CRITERIA:\n\n* Post-partum women\n* 18 years or older\n* Delivered within 5 years from the study visit\n* History of gestational diabetes diagnosed by an obstetrician and confirmed according to the American College of Obstetricians and Gynecologists criteria for gestational diabetes OR history of uncomplicated pregnancy (defined as no history of gestational diabetes, hypertensive pregnancy, or other gestational disorder).\n\nEXCLUSION CRITERIA: We exclude participants from both groups for:\n\n* Skin diseases\n* Current tobacco use\n* Diagnosed or suspected hepatic or metabolic disease including diabetes\n* Diagnosed with depression or other mood-related disorders, asthma, chronic obstructive pulmonary disease, cystic fibrosis, or pulmonary fibrosis\n* Use of prescribed NSAIDs, statins or other cholesterol-lowering medication, antihypertensive medication, carbonic anhydrase inhibitors, corticosteroids, thyroid medications, antidepressants or mood stabilizers, diuretics, phenothiazines, or benzodiazepines\n* History of preeclampsia or gestational hypertension,\n* History or family history of panic disorder,\n* Currently pregnant\n* Body mass index \\\u003C18.5 kg\u002Fm2,\n* Allergy to materials used during the experiment (e.g. latex), known allergies to study drugs.\n* History of heavy alcohol use\u002Fbinge drinking,\n* Have planned procedures with radiological contrast,\n* Have a major dental procedure\u002Fsurgery coming up, such as a dental extraction\n* Anatomy of the middle cerebral artery or internal carotid artery that prevents adequate ultrasonography and\u002For and data collection",{"count":420,"type":23},[614],"PHASE1","Gestational Diabetes Mellitus (GDM) currently affects approximately 14% of all pregnancies worldwide. Importantly, the health-related consequences of GDM extend well beyond pregnancy, such that women with a history of GDM have a 40% increased risk of cerebrovascular diseases and a 67% increased risk of dementia, compared to women with a history of uncomplicated pregnancy. Women with a history of GDM have impaired skin microvascular function, compared with women with a history of uncomplicated pregnancy. Therefore, it's likely that GDM results in impaired brain blood vessel function, yet there is little-to-no information regarding the effects of GDM on brain blood vessel health and function after pregnancy.\n\nTherefore, the purpose of the study is to evaluate the effects of GDM on brain blood flow and brain blood vessel function in healthy women with either a history of GDM or uncomplicated pregnancy.\n\nIn this study, the investigators will use two different types of ultrasound to non-invasively measure brain blood flow. Brain blood vessel function will be evaluated by examining the brain blood flow responses to increases in carbon dioxide (the increases in carbon dioxide are similar to what is experienced during a breath hold). Additionally, the investigators will compare the brain blood flow results to skin microvascular function to explore potential mechanisms behind possible impairments in brain blood vessel function. Skin microvascular function will be assessed using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) on dime sized areas of the forearm. Finally, for screening purposes and to further explore potential mechanisms behind any potential impairments in brain blood vessel function, the investigators will perform blood draws to determine the metabolic health of the participants and to analyze for substances that influence blood vessel function.",[29,617,618],"Postpartum Women","Uncomplicated Pregnancy",[268,620,36,621],"Brain Blood Flow","Postpartum","2025-12-08",{"date":526,"type":47},{"date":625,"type":47},"2025-08-22",{"date":627,"type":23},"2028-04-15",{"name":629,"class":54},"Anna Stanhewicz, PhD",{"id":631,"slug":632,"hasResults":12,"nctId":633,"briefTitle":634,"officialTitle":635,"acronym":636,"eligibilityCriteria":637,"healthyVolunteers":12,"sex":19,"minAge":91,"maxAge":4,"enrollmentInfo":638,"targetDuration":4,"studyType":157,"phases":4,"briefSummary":640,"conditions":641,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":645,"lastUpdatePostDateStruct":646,"startDateStruct":648,"completionDateStruct":650,"leadSponsor":652,"locationsCount":83},"100583420","sarcopenia-in-gestational-diabetes-100583420","NCT06876090","Sarcopenia in Gestational Diabetes","Sarcopenia in Gestational Diabetes: The SiGnal-D Study","SiGnal-D","Inclusion Criteria:\n\nAt least one among the following conditions:\n\n* Age equal to or higher than 35 years;\n* Body mass index (BMI) equal to or higher than 25 kg\u002Fm\\^2;\n* Glycemia between 5.6 and 6.9 mmol\u002FL before or at the beginning of pregnancy;\n* Fetal macrosomia in previous pregnancy;\n* GDM in previous pregnancy;\n* First-degree family history of diabetes.\n\nExclusion Criteria:\n\n* Unmatching of at least one among the inclusion criteria;\n* Twin pregnancy;\n* Presence of any already known disease\u002Fdisorder possibly affecting muscle mass or function;\n* Neurological or psychiatric diseases;\n* Already known diabetes (e.g., type 1 or type 2 diabetes).",{"count":639,"type":23},200,"Sarcopenia is a syndrome characterized by loss of skeletal muscle mass and strength, and physical performance deterioration. Prevalence of sarcopenia in elderly people is remarkably high (prevalence of about 25% in 60+ years people). In type 2 diabetes (T2D), sarcopenia is emerging as comorbidity of major concern. Sarcopenia, however, is not limited to elderly people, as it can develop also in younger individuals with prevalence around 9% or even higher according to some investigators. Of note, sarcopenia has been reported even in the 20-29 years interval. This interval includes women of childbearing age, thus raising the question whether sarcopenia may occur also in women with gestational diabetes (GDM) and whether this may affect pregnancy outcomes. Also, association between sarcopenia and cognitive impairment has been repeatedly reported, to the point that some authors have emphasized the importance of early sarcopenia recognition for prevention of cognitive impairment. Therefore, our main aims are:\n\n1. To ascertain whether sarcopenia is present in GDM and, in that case, its prevalence;\n2. To identify risk factors for sarcopenia;\n3. To determine sarcopenia impact on pregnancy outcomes, and cognitive function.\n\nDuring pregnancy, all women will undergo oral glucose tolerance test (OGTT) for assessment of the glucometabolic condition. Several clinical variables of interest in sarcopenia will also be recorded. As regards the OGTT data, special focus will be on the assessment of insulin resistance, both at fasting and during the dynamic conditions determined by the OGTT. Notably, the special interest for insulin resistance is due to the reason that this type of metabolic alteration is known to be a risk factor for sarcopenia. In fact, all women will then undergo testing for diagnosis of sarcopenia (or presarcopenia), and all data and parameters will be analyzed to identify relationships between sarcopenia-related variables and GDM-related ones. It is worth noting that in consideration of the exacerbated insulin resistance condition often observed in GDM, the investigators expect indeed a not negligible prevalence of sarcopenia (or at least presarcopenia) in GDM women, despite the young (non-elderly) age. In addition, since insulin resistance is often present in pregnancy even in the absence of dysglycemia, the investigators do not exclude to identify some cases of sarcopenia\u002Fpresarcopenia even in pregnant non-GDM women. This study will be the basis for future studies (also of interventional type), especially in women with GDM for prevention of sarcopenia and related possible pregnancy complication and adverse pregnancy outcomes, as well as for possibly contributing to mitigation of risk for T2D development in later life.",[642,29,98,643,644],"Sarcopenia","Adverse Maternal and Neonatal Outcomes","Cognitive Function","2025-11-18",{"date":647,"type":47},"2025-11-21",{"date":649,"type":47},"2025-05-28",{"date":651,"type":23},"2026-04",{"name":653,"class":654},"Istituto di Neuroscienze Consiglio Nazionale delle Ricerche","NETWORK",{"id":656,"slug":657,"hasResults":12,"nctId":658,"briefTitle":659,"officialTitle":660,"acronym":661,"eligibilityCriteria":662,"healthyVolunteers":12,"sex":19,"minAge":663,"maxAge":4,"enrollmentInfo":664,"targetDuration":4,"studyType":24,"phases":666,"briefSummary":667,"conditions":668,"keywords":669,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":672,"lastUpdatePostDateStruct":673,"startDateStruct":674,"completionDateStruct":676,"leadSponsor":678,"locationsCount":114},"100565358","the-feasibility-of-expectant-management-versus-induction-at-38-weeks-among-individuals-with-gestational-diabetes-mellitus-a-randomized-controlled-pilot-trial-eager-pilot-trial-100565358","NCT06641141","The Feasibility Of Expectant Management Versus Induction At 38 Weeks Among Individuals With Gestational Diabetes Mellitus: A Randomized Controlled Pilot Trial (EAGER Pilot Trial)","The Feasibility Of Expectant Management Versus Induction At 38 Weeks Among Individuals With Gestational Diabetes Mellitus: A Randomized Controlled Pilot Trial","EAGER Pilot","Inclusion Criteria:\n\n* Diagnosis of GDM after 24 weeks of gestation, based on documented 1-step or 2-step screening and diagnostic tests for GDM.\n* Singleton fetus at randomization.\n* Confirmed live fetus within 24 hours prior to randomization.\n* Gestational age between 36 weeks + 0 days and 38 weeks + 0 days inclusive based on an ultrasound in the first or second trimester \\[≤ 23 weeks + 0 days\\]. For pregnancies conceived by in vitro fertilization, dating will be based on the embryo age at transfer.\n* Cephalic presentation.\n* Planning to deliver at a participating site.\n* Aged 16 years or older.\n\nExclusion Criteria:\n\n* Pre-pregnancy diabetes mellitus.\n* Any obstetrical\u002Fmaternal indication for immediate delivery including placenta abruption, abnormal fetal well-being either by non-stress test or biophysical profile, history of venous thromboembolism (VTE) on low molecular weight heparin, pre-existing hypertension, gestational hypertension, preeclampsia, eclampsia, or Hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome at the time of randomization.\n* Contraindication to labour and\u002For vaginal delivery.\n* Signs of labour (regular uterine contractions accompanied by cervical dilation and\u002For effacement) at the time of randomization.\n* Significant vaginal bleeding or ruptured membranes at the time of randomization.\n* Prior Cesarean delivery.\n* Placenta previa, placenta accreta, or vasa previa.\n* Cerclage in current pregnancy.\n* Known major fetal anomaly (e.g., gastroschisis, congenital heart defects).\n* Known oligohydramnios (AFI \\\u003C 5 or MVP \\\u003C 2 or no 2 by 2 pocket).\n* Known fetal growth restriction (EFW \\\u003C 3rd percentile).\n* Refusal of blood products.\n* Use of unregulated substances.","16 Years",{"count":665,"type":23},260,[26],"The EAGER pilot trial is designed to assess the feasibility of a Canadian, multicentre prospective randomized open-label blinded end-point (PROBE) clinical trial addressing whether induction of labour (IOL) at 38 weeks' gestation compared to expectant management (EM) reduces severe perinatal mortality and morbidity among individuals with gestational diabetes mellitus (GDM). Eligible participants will be consented between 32 weeks + 0 days and 38 weeks + 0 days gestation and randomized between 36 weeks + 0 days and 38 weeks + 0 days gestation. Participants will be randomized to one of two arms:\n\n* Intervention Arm: IOL between 38 weeks + 0 days and 38 weeks + 6 days OR\n* Control Arm: EM without intervention until spontaneous labour, or earlier if a medical indication arises.\n\nA total of 260 participants (130 per group) will be recruited from Canadian sites, where participants will have 3 study visits:\n\n1. Enrollment and randomization\n2. After delivery and up to 72 hours postpartum\n3. 6 weeks postpartum At enrollment and randomization, patient-reported baseline and clinical data from medical charts will be collected. Upon admission to hospital for labour and delivery, a blood sample may be collected to assess HbA1C and plasma glucose levels. After delivery and up to 72 hours postpartum, study feasibility will be assessed through patient-reported outcomes and administrative and clinical data. At 6 weeks postpartum, participants will be surveyed for secondary health resource use. Findings from this pilot will inform the design, implementation and feasibility of a future full-scale randomized controlled trial.",[29],[548,103,670,671],"induction","induction of labour","2025-11-14",{"date":645,"type":47},{"date":675,"type":47},"2025-04-07",{"date":677,"type":23},"2028-03",{"name":679,"class":54},"Ottawa Hospital Research Institute",{"id":681,"slug":682,"hasResults":12,"nctId":683,"briefTitle":684,"officialTitle":684,"acronym":685,"eligibilityCriteria":686,"healthyVolunteers":12,"sex":19,"minAge":61,"maxAge":4,"enrollmentInfo":687,"targetDuration":688,"studyType":157,"phases":4,"briefSummary":689,"conditions":690,"keywords":691,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":695,"lastUpdatePostDateStruct":696,"startDateStruct":698,"completionDateStruct":700,"leadSponsor":701,"locationsCount":172},"100610727","insulin-resistance-in-gestational-diabetes-mellitus-100610727","NCT07231341","Insulin Resistance in Gestational Diabetes Mellitus","IRIS","Inclusion Criteria:\n\n* All singleton pregnant women with gestational diabetes mellitus (GDM) between gestational age (GA) 28+0 and 34+6 attending the obstetric outpatient clinic at Aarhus University Hospital, Aarhus, Denmark or Gødstrup Hospital, Herning, Denmark will be offered participation.\n\nExclusion Criteria:\n\n* Pre-gestational diabetes\n* Age \\\u003C 18 years\n* Multiple pregnancies\n* Chronic disease that is not well-controlled and is expected to influence study outcomes (including inflammatory diseases such as rheumatologic, gastroenterological, etc.)\n* Treatment with systemic corticosteroids\n* Smoking\n* Women who are unable to understand the oral and written patient information",{"count":206,"type":23},"12 Weeks","This prospective cohort study investigates glycaemic variability, assessed by continuous glucose monitoring (CGM), in pregnant women with gestational diabetes mellitus (GDM) and its association with fetal growth and related maternal and neonatal outcomes. Participants will undergo 14 days of CGM during pregnancy to characterise individual glycaemic patterns. Clinical and paraclinical data, including fasting plasma glucose, HbA1c, lipid profile, organ markers of pregnancy-related medical conditions, maternal weight gain, and blood pressure will be collected at two study visits. Oral glucose tolerance test (OGTT) 2-hour values will be obtained at diagnosis. All participants will receive standard GDM care and routine obstetric follow-up for assessment of fetal growth and wellbeing. Birth weight, birth weight z-scores, and relevant neonatal outcomes will be recorded after delivery.\n\nStatistical analyses will be performed using Stata statistical software (StataCorp LLC, College Station, TX, USA). Continuous and categorical variables will be summarised using appropriate descriptive statistics. Associations between maternal glycaemic variability and neonatal as well as other maternal metabolic outcomes will be explored using suitable statistical methods, with adjustment for relevant covariates. Exploratory analyses may include additional glycaemic variability metrics and lipid parameters to further characterise maternal metabolic patterns.",[29],[89,35,692,693,36,694],"CGM","Continuous glucose monitoring","Diabetes in pregnancy","2025-11-13",{"date":697,"type":47},"2025-11-17",{"date":699,"type":47},"2022-09-22",{"date":651,"type":23},{"name":702,"class":54},"University of Aarhus"]